Investigation of the mechanism and advancements in diagnosis and management of hypothyroidism triggered by immune checkpoint inhibitors
Hu Jinhong
Yang Jili
Cheng Qi
Wang Yan
Zeng Chuanfu
Zhang Shengjiao
Abstract：The emergence of immune checkpoint inhibitors(ICI)marks the arrival of a new era in cancer immunotherapy,bringing unprecedented long-term survival benefits to cancer patients.ICI is currently widely used in multi-line treatment of cancer,but a large amount of clinical data shows that it may also lead to the occurrence of immune-related adverse events(irAEs)while bringing therapeutic benefits.Among them,ICI-related hypothy-roidism(irH)is one of the most common irAEs.Because it has a hidden onset and the disease progresses relatively slowly,it is often missed in clinical practice.Severe cases may lead to mucous edema coma,heart failure,and respiratory failure,which pose significant challenges for treatment and prognosis.Therefore,it is crucial to correctly understand and effectively manage irH to improve the safety and prognosis of cancer patients.This article will provide a comprehensive review of irH,including its pathogenesis,risk factors,diagnostic criteria,modern medical treatment,and Chinese medicine intervention.
Keywords：HypothyroidismImmune checkpoint inhibitorsImmune-related adverse events
Publication Date：2024-11-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 1742-1746 )